Q-omics provides the consensus-scored C1orf127 profile across patient tissues and cancer cell-line models. C1orf127 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, C1orf127 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, C1orf127 RNA expression shows 12,052 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KIRC, and THYM as cancer lineages where C1orf127 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1orf127 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1orf127 survival associations across molecular data types. C1orf127 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1orf127 RNA expression–survival associations across cancer types. High C1orf127 expression shows unfavorable associations in BRCA, ACC, UVM, LAML and COAD, but favorable associations in HNSC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for C1orf127 RNA expression.
This table summarizes C1orf127 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C1orf127. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1orf127 shows lower tumor expression in LUSC, HNSC and THCA and higher tumor expression in KIRC, KIRP and BRCA. The KIRC box plot shows higher C1orf127 RNA expression in tumor versus normal tissue (log2 FC = +0.376, t-test p < 0.001).
This table shows molecular features associated with C1orf127 in patient tissues and cancer cell lines. In patient samples, C1orf127 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C1orf127 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
